Last reviewed · How we verify
Glargine and regular insulin versus NPH and regular insulin
At a glance
| Generic name | Glargine and regular insulin versus NPH and regular insulin |
|---|---|
| Sponsor | King Edward Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients. (PHASE4)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) (NA)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (NA)
- RCT Glargine vs NPH for Treatment of DM in Pregnancy (PHASE3)
- Insulin Glargine Versus Twice-Daily NPH (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: